Advance progress in immunotherapy for unresectable locally advanced non-small cell lung cancer
10.11904/j.issn.1002-3070.2025.01.010
- VernacularTitle:不可切除局部晚期非小细胞肺癌免疫治疗进展
- Author:
Caizheng LI
1
;
Jing ZHENG
;
Qiaoli SU
Author Information
1. 四川大学华西医院全科医学中心(成都 610041)
- Publication Type:Journal Article
- Keywords:
Locally advanced non-small cell lung cancer;
Concurrent chemoradiotherapy;
Adverse events;
Immunotherapy
- From:
Practical Oncology Journal
2025;39(1):67-72
- CountryChina
- Language:Chinese
-
Abstract:
The conventional treatment for unresectable local advanced non-small cell lung cancer(NSCLC)is concurrent chemoradiotherapy followed by continued immune maintenance therapy for one year.However,due to the fact that most patients cannot tolerate concurrent chemotherapy,this treatment regimen has not achieved the expected results.For these patients,the combination of radiotherapy and immunotherapy is a more effective treatment strategy that can improve efficacy while ensuring safety.However,due to the high heterogeneity of patients with stage Ⅲ NSCLC,their tumor burden varies,and most patients have larger tumor volumes,the side effects caused by radiotherapy also increase accordingly,making it difficult for some patients to subsequent complete the immune maintenance therapy.For patients with larger tumor volumes,the current treatment plan is to first undergo two cycles of induction chemotherapy to shrink the tumor.Recent studies have found that adding synchronous immunotherapy during induction chemotherapy has a more significant tumor reducing effect,demonstrating promising therapeutic value.Many studies have shown that circulating tumor DNA and peripheral blood tumor mutation burden have become predictive indicators for the prognosis and immunotherapy effica-cy of various advanced tumors,and are expected to guide clinicians to develop individualized immunotherapy plans in the future.This article reviews the progress of immunotherapy for unresectable locally advanced NSCLC.
